Precigen (PGEN) Cash from Investing Activities (2012 - 2026)
Precigen (PGEN) posted quarterly Cash from Investing Activities of $21.0 million for Q1 2026, up 424.72% year-over-year from $4.0 million in Q1 2025, and down 47.41% quarter-over-quarter from $39.9 million in Q4 2025.
Analysis
Precigen (PGEN) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Cash from Investing Activities for 15 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 424.72% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $25.9 million (up 150.55% YoY), while the FY2025 annual figure was -$1.5 million, up 92.59% from the prior year.
- Cash from Investing Activities retreated to $21.0 million in Q1 2026 per PGEN's latest filing, from $39.9 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $181.9 million in Q3 2022 and bottomed at -$65.4 million in Q4 2024.
- Historically, Cash from Investing Activities has averaged $13.1 million across 5 years, with a median of $15.0 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 726.13% — and 2025, when it slumped 1221.28%.
- Precigen's Cash from Investing Activities stood at $11.4 million in 2022, then climbed by 16.39% to $13.3 million in 2023, then plunged by 591.74% to -$65.4 million in 2024, then surged by 160.99% to $39.9 million in 2025, then slumped by 47.41% to $21.0 million in 2026.
- Business Quant data shows PGEN's Cash from Investing Activities at $21.0 million in Q1 2026, $39.9 million in Q4 2025, and -$63.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 26.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.69 Mn |
| Mar 31, 2026 | 20.97 Mn |
| Dec 31, 2025 | 39.87 Mn |
| Sep 30, 2025 | -63.39 Mn |
| Jun 30, 2025 | 28.44 Mn |
| Mar 31, 2025 | -6.46 Mn |
| Dec 31, 2024 | -65.37 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Mar 31, 2024 | 24.05 Mn |
| Dec 31, 2023 | 13.29 Mn |
| Sep 30, 2023 | 10.53 Mn |
| Jun 30, 2023 | 23.50 Mn |
| Mar 31, 2023 | -50.41 Mn |
| Dec 31, 2022 | 11.42 Mn |
| Sep 30, 2022 | 181.86 Mn |
| Jun 30, 2022 | 16.57 Mn |
| Mar 31, 2022 | 16.57 Mn |
| Dec 31, 2021 | 15.93 Mn |
| Sep 30, 2021 | 22.01 Mn |